Testing an injected medication for sleep apnea in people with obesity
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests an injected medication called HDM1005 to see if it helps reduce sleep apnea events in people who are obese and already use a CPAP or other PAP machine. You will continue using your PAP device during the study, and the medication may improve your sleep apnea and help with weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your BMI is 28 or higher.
- You have been diagnosed with obstructive sleep apnea and have at least 15 apnea/hypopnea events per hour on a sleep test.
- You have used a PAP machine for at least 3 months and are willing to continue (with brief pauses before sleep tests).
- You have not had significant weight changes (more than 5%) in the last 90 days.
- You do not have diabetes, certain thyroid conditions, other sleep disorders, significant lung disease, uncontrolled high blood pressure, obesity from other causes, recent cancer, or a recent stroke/heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an injected medication to see if it helps reduce the severity of obstructive sleep apnea in people with obesity. The trial will compare the drug to a placebo over several months to check safety and effectiveness.
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
This trial tests an injectable medication (HRS9531) to see if it helps people with both obstructive sleep apnea and obesity. It compares the drug to a placebo (no active medicine) to check safety and effectiveness.
This trial tests an injection called GZR18 to see if it helps people with obesity and obstructive sleep apnea who already use a CPAP machine. It may lead to weight loss and improve sleep apnea.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
This study tests an investigational medication (IBI362) to see if it can improve sleep apnea in people with obesity. You might qualify if you have moderate to severe sleep apnea and a BMI of 28 or higher, whether or not you currently use a CPAP machine.
Hear when a new Obstructive Sleep Apnea (OSA) and Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.